Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays
Background and aims - Lipoprotein (a) [Lp(a)] is an established causal risk factor for cardiovascular disease (CVD), independently of low-density lipoproteins (LDL) and other risk factors. The recognition of Lp(a) as an atherogenic molecule has raised the demand for reliable quantification methods i...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
27 August 2019
|
| In: |
Atherosclerosis
Year: 2019, Volume: 289, Pages: 206-213 |
| ISSN: | 1879-1484 |
| DOI: | 10.1016/j.atherosclerosis.2019.08.015 |
| Online Access: | Verlag, Volltext: https://doi.org/10.1016/j.atherosclerosis.2019.08.015 Verlag: http://www.sciencedirect.com/science/article/pii/S0021915019314601 
|
| Author Notes: | Hubert Scharnagl, Tatjana Stojakovic, Benjamin Dieplinger, Hans Dieplinger, Gertraud Erhart, Gerhard M. Kostner, Markus Herrmann, Winfried März, Tanja B. Grammer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1685680828 | ||
| 003 | DE-627 | ||
| 005 | 20240403193313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191216s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.atherosclerosis.2019.08.015 |2 doi | |
| 035 | |a (DE-627)1685680828 | ||
| 035 | |a (DE-599)KXP1685680828 | ||
| 035 | |a (OCoLC)1341282125 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Scharnagl, Hubert |e VerfasserIn |0 (DE-588)1100175954 |0 (DE-627)859149919 |0 (DE-576)18647525X |4 aut | |
| 245 | 1 | 0 | |a Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays |c Hubert Scharnagl, Tatjana Stojakovic, Benjamin Dieplinger, Hans Dieplinger, Gertraud Erhart, Gerhard M. Kostner, Markus Herrmann, Winfried März, Tanja B. Grammer |
| 264 | 1 | |c 27 August 2019 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 16.12.2019 | ||
| 520 | |a Background and aims - Lipoprotein (a) [Lp(a)] is an established causal risk factor for cardiovascular disease (CVD), independently of low-density lipoproteins (LDL) and other risk factors. The recognition of Lp(a) as an atherogenic molecule has raised the demand for reliable quantification methods in the clinical laboratory. The aim of this work is to compare commercial immunochemical assays. - Methods - We measured Lp(a) serum concentrations using six different assays, providing Lp(a) in mg/dl (Denka Seiken, Abbott Quantia, Beckman, Diasys 21FS, and Siemens N Latex) or in nmol/l (Roche TinaQuant, Diasys 21 FS) in 144 serum samples covering the clinically relevant range of Lp(a) concentrations. All assays relied on five-point calibrations using calibrators provided by the manufacturers. Apolipoprotein(a) phenotyping was performed by sodium dodecyl sulfate-agarose gel electrophoresis (SDS-agarose) followed by immunoblotting. - Results - Most bivariate correlation coefficients were greater than 0.90. Compared to an established IFCC-proposed reference material, the results of the different assays diverged from the target values (43.3 mg/dl or 96.6 nmol/l) by −8% (Siemens N Latex) and +22% (Abbott Quantia). Stratification of the samples into five groups with increasing Lp(a) concentrations and difference plots showed that the differences among assays were concentration-dependent. Some assays overestimated Lp(a) at high concentrations compared to the Denka Seiken assay. - Conclusions - Current commercial immunological assays for measuring Lp(a) concentrations are differently calibrated. Their biases differ significantly across the clinically relevant concentration range in a non-linear manner. This is not conclusively explained by apolipoprotein (a) phenotypes. Further international efforts to harmonize assays for Lp(a) are needed. | ||
| 650 | 4 | |a Atherosclerosis | |
| 650 | 4 | |a Harmonization | |
| 650 | 4 | |a Lipoprotein (a) assays | |
| 650 | 4 | |a Myocardial infarction | |
| 700 | 1 | |a Stojakovic, Tatjana |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dieplinger, Benjamin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dieplinger, Hans |e VerfasserIn |4 aut | |
| 700 | 1 | |a Erhart, Gertraud |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kostner, Gerhard M. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herrmann, Markus |e VerfasserIn |4 aut | |
| 700 | 1 | |a März, Winfried |d 1958- |e VerfasserIn |0 (DE-588)1027603599 |0 (DE-627)729463605 |0 (DE-576)373454635 |4 aut | |
| 700 | 1 | |a Grammer, Tanja B. |d 1972- |e VerfasserIn |0 (DE-588)1030134952 |0 (DE-627)734830041 |0 (DE-576)377941018 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Atherosclerosis |d Amsterdam [u.a.] : Elsevier Science, 1970 |g 289(2019), Seite 206-213 |h Online-Ressource |w (DE-627)306654091 |w (DE-600)1499887-7 |w (DE-576)081984545 |x 1879-1484 |7 nnas |a Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays |
| 773 | 1 | 8 | |g volume:289 |g year:2019 |g pages:206-213 |g extent:8 |a Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.atherosclerosis.2019.08.015 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0021915019314601 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191216 | ||
| 993 | |a Article | ||
| 994 | |a 2019 | ||
| 998 | |g 1030134952 |a Grammer, Tanja B. |m 1030134952:Grammer, Tanja B. |d 60000 |d 65300 |e 60000PG1030134952 |e 65300PG1030134952 |k 0/60000/ |k 1/60000/65300/ |p 9 |y j | ||
| 998 | |g 1027603599 |a März, Winfried |m 1027603599:März, Winfried |d 60000 |d 61400 |e 60000PM1027603599 |e 61400PM1027603599 |k 0/60000/ |k 1/60000/61400/ |p 8 | ||
| 999 | |a KXP-PPN1685680828 |e 3565669934 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-journal"},"origin":[{"dateIssuedDisp":"27 August 2019","dateIssuedKey":"2019"}],"recId":"1685680828","relHost":[{"pubHistory":["Nachgewiesen 11.1970 -"],"part":{"extent":"8","pages":"206-213","text":"289(2019), Seite 206-213","year":"2019","volume":"289"},"language":["eng"],"title":[{"title_sort":"Atherosclerosis","title":"Atherosclerosis"}],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"publisher":"Elsevier Science","dateIssuedDisp":"[1970?]-","publisherPlace":"Amsterdam [u.a.]"}],"recId":"306654091","note":["Gesehen am 14.10.2020"],"id":{"issn":["1879-1484"],"zdb":["1499887-7"],"eki":["306654091"]},"physDesc":[{"extent":"Online-Ressource"}],"disp":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassaysAtherosclerosis"}],"note":["Gesehen am 16.12.2019"],"id":{"eki":["1685680828"],"doi":["10.1016/j.atherosclerosis.2019.08.015"]},"physDesc":[{"extent":"8 S."}],"name":{"displayForm":["Hubert Scharnagl, Tatjana Stojakovic, Benjamin Dieplinger, Hans Dieplinger, Gertraud Erhart, Gerhard M. Kostner, Markus Herrmann, Winfried März, Tanja B. Grammer"]},"person":[{"family":"Scharnagl","display":"Scharnagl, Hubert","given":"Hubert","role":"aut"},{"family":"Stojakovic","display":"Stojakovic, Tatjana","given":"Tatjana","role":"aut"},{"family":"Dieplinger","display":"Dieplinger, Benjamin","role":"aut","given":"Benjamin"},{"given":"Hans","role":"aut","display":"Dieplinger, Hans","family":"Dieplinger"},{"family":"Erhart","given":"Gertraud","role":"aut","display":"Erhart, Gertraud"},{"family":"Kostner","role":"aut","given":"Gerhard M.","display":"Kostner, Gerhard M."},{"role":"aut","given":"Markus","display":"Herrmann, Markus","family":"Herrmann"},{"display":"März, Winfried","role":"aut","given":"Winfried","family":"März"},{"family":"Grammer","display":"Grammer, Tanja B.","given":"Tanja B.","role":"aut"}],"language":["eng"],"title":[{"title_sort":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays"}]} | ||
| SRT | |a SCHARNAGLHCOMPARISON2720 | ||